In the present study, treatment with a neutralizing mAb against ALK7 caused a substantial loss of adipose mass and improved glucose intolerance and insulin resistance in both genetic and diet-induced mouse obesity models. Here, ACVR1C is linked to obesity due to melanocortin 4 receptor deficiency.